U.S. markets close in 15 minutes

Structure Therapeutics Inc. (GPCR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
61.01-0.49 (-0.80%)
As of 03:40PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close61.50
Bid60.50 x 1100
Ask60.62 x 900
Day's Range60.38 - 63.30
52 Week Range20.80 - 75.02
Avg. Volume958,668
Market Cap2.83B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.01
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est89.17
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for GPCR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Structure Therapeutics Inc.
    Daily – Vickers Top Buyers & Sellers for 11/27/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    9 days agoArgus Research
View more
  • InvestorPlace

    If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names

    Some of the hottest opportunities can be found in biotech stocks. Look at gene editing companies, like CRISPR Therapeutics (NASDAQ:CRSP), for example. Since the start of November, CRSP ran from about $40 to $70.60 on a favorable US FDA advisory panel review of its sickle cell treatment. Now, as it nears its Dec. 8 PDUFA date it could still see higher highs. Or, look at what just happened with biotech stocks, like SpringWorks Therapeutics (NASDAQ:SWTX). The biotech popped from about $21 to $26.04

  • Insider Monkey

    11 Best Young Stocks to Buy and Hold For 20 Years

    In this article, we will take a look at the 11 best young stocks to buy and hold for 20 years. To skip our analysis of the recent market trends and market activity, you can go directly to see the 5 Best Young Stocks to Buy and Hold For 20 Years. The global equity markets […]

  • Insider Monkey

    11 Best Upside Stocks To Buy Right Now

    In this piece, we will take a look at the 11 best upside stocks to buy right now. If you want to skip our overview of share valuation, then take a look at the 5 Best Upside Stocks To Buy Now. The art of buying shares on the market has always gone hand in hand […]